JP2019500012A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500012A5
JP2019500012A5 JP2018522004A JP2018522004A JP2019500012A5 JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5 JP 2018522004 A JP2018522004 A JP 2018522004A JP 2018522004 A JP2018522004 A JP 2018522004A JP 2019500012 A5 JP2019500012 A5 JP 2019500012A5
Authority
JP
Japan
Prior art keywords
cell
seq
cells
polypeptide
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522004A
Other languages
English (en)
Japanese (ja)
Other versions
JP7104624B2 (ja
JP2019500012A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/059444 external-priority patent/WO2017075433A1/en
Publication of JP2019500012A publication Critical patent/JP2019500012A/ja
Publication of JP2019500012A5 publication Critical patent/JP2019500012A5/ja
Priority to JP2022110653A priority Critical patent/JP7539434B2/ja
Application granted granted Critical
Publication of JP7104624B2 publication Critical patent/JP7104624B2/ja
Priority to JP2024134780A priority patent/JP2024155943A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522004A 2015-10-30 2016-10-28 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法 Active JP7104624B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022110653A JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248685P 2015-10-30 2015-10-30
US62/248,685 2015-10-30
PCT/US2016/059444 WO2017075433A1 (en) 2015-10-30 2016-10-28 Transforming growth factor-beta-responsive polypeptides and their methods for use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022110653A Division JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019500012A JP2019500012A (ja) 2019-01-10
JP2019500012A5 true JP2019500012A5 (enExample) 2019-12-05
JP7104624B2 JP7104624B2 (ja) 2022-07-21

Family

ID=58631218

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018522004A Active JP7104624B2 (ja) 2015-10-30 2016-10-28 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2022110653A Active JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A Pending JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022110653A Active JP7539434B2 (ja) 2015-10-30 2022-07-08 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法
JP2024134780A Pending JP2024155943A (ja) 2015-10-30 2024-08-13 トランスフォーミング増殖因子ベータ応答性ポリペプチド及びその使用方法

Country Status (17)

Country Link
US (3) US11014980B2 (enExample)
EP (2) EP3368571B1 (enExample)
JP (3) JP7104624B2 (enExample)
KR (1) KR102771979B1 (enExample)
CN (2) CN115960264A (enExample)
DK (1) DK3368571T5 (enExample)
ES (1) ES2935372T3 (enExample)
FI (1) FI3368571T3 (enExample)
HR (1) HRP20230239T1 (enExample)
HU (1) HUE061424T2 (enExample)
LT (1) LT3368571T (enExample)
PL (1) PL3368571T3 (enExample)
PT (1) PT3368571T (enExample)
RS (1) RS64053B1 (enExample)
SI (1) SI3368571T1 (enExample)
SM (1) SMT202300027T1 (enExample)
WO (1) WO2017075433A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3368571B1 (en) * 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
RU2018138122A (ru) * 2016-04-05 2020-05-12 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новая терапия
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
WO2019004794A1 (ko) 2017-06-30 2019-01-03 코오롱생명과학 주식회사 골관절염 예방 또는 치료용 약학적 조성물
CN109486745A (zh) * 2017-09-12 2019-03-19 中国人民解放军第三军医大学第附属医院 Fg-4592在促进表皮干细胞迁移方面的应用
CN111684061B (zh) 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
BR112022003553A2 (pt) 2019-08-30 2022-05-24 Allogene Therapeutics Inc Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta
CN111748043B (zh) * 2020-07-03 2022-09-02 深圳市体内生物医药科技有限公司 一种嵌合抗原受体及其应用
WO2022046935A2 (en) * 2020-08-26 2022-03-03 The Regents Of The University Of California Methods and compositions for treating glioblastoma
CN112500491B (zh) * 2020-12-18 2022-04-08 深圳市迈加瑞生物技术有限公司 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
US20240336903A1 (en) * 2021-08-19 2024-10-10 Shandong Boan Biotechnology Co., Ltd. Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
US20250250329A1 (en) * 2022-04-11 2025-08-07 The Board Of Trustees Of The Leland Stanford Junior University Cytokine adaptor proteins and uses thereof
EP4509522A1 (en) 2023-08-16 2025-02-19 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same
WO2025096419A1 (en) * 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5138941A (en) 1991-06-28 1992-08-18 Strauss Frederick J Wooden crusher for recyclable metal cans
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
WO1998050432A1 (en) 1997-05-07 1998-11-12 Bristol-Myers Squibb Company Recombinant antibody-enzyme fusion proteins
CA2306443A1 (en) 1997-10-14 1999-04-22 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7066469B2 (en) 2002-08-06 2006-06-27 University of Kentucky Research Foundation Board of Supervisors of Louisiana State University Seal assembly for machinery housing
US20040043949A1 (en) 2002-08-30 2004-03-04 Christopher Richardson Therapeutic system targeting pathogen proteases and uses thereof
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004085611A2 (en) 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
US20050125852A1 (en) * 2003-05-09 2005-06-09 Sugen, Inc. Novel kinases
CA2531118C (en) 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
SG145712A1 (en) 2003-08-01 2008-09-29 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
AU2004292180A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−6阻害剤
CA2597098C (en) * 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
US20090068158A1 (en) 2005-12-09 2009-03-12 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CN101330914A (zh) 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
CN101827857A (zh) * 2007-08-03 2010-09-08 埃斯特瑞恩有限公司 粒细胞集落刺激因子
JP5654986B2 (ja) 2008-06-30 2015-01-14 モーフオテク・インコーポレーテツド 抗gd2抗体並びにそれに関連する方法及び使用
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
US8969082B2 (en) 2009-06-26 2015-03-03 Sea Lane Biotechnologies, Llc Expression of surrogate light chains
EP2566954B2 (en) 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2809568C (en) * 2010-09-01 2019-06-11 Genzyme Corporation Treatment of myocardial infarction using tgf - beta antagonists
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
KR101933197B1 (ko) 2010-11-08 2018-12-27 제넨테크, 인크. 피하 투여용 항―il―6 수용체 항체
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013002362A1 (ja) * 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
EP2730289A1 (en) 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
US9562110B2 (en) 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
JP6495884B2 (ja) 2013-03-11 2019-04-03 ジェンザイム・コーポレーション 改変抗tgfベータ抗体および抗原結合フラグメント
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
EP3243831A1 (en) 2014-02-27 2017-11-15 Ucl Business Plc Variants of the proliferation-inducing ligand (april)
TR201910814T4 (tr) * 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3131927B8 (en) * 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3227323B1 (en) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US10647778B2 (en) 2015-02-09 2020-05-12 University Of Florida Research Foundation, Incorporated Bi-specific chimeric antigen receptor and uses thereof
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3368571B1 (en) * 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
CA3020993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
CN109562126A (zh) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN117298260A (zh) 2016-09-02 2023-12-29 莱蒂恩技术公司 用DuoCAR治疗癌症的组合物和方法
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CN108148863B (zh) 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
AU2018309735B2 (en) 2017-07-31 2025-03-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
BR112020005938A2 (pt) 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
MA51428A (fr) 2017-12-22 2020-11-04 Bluebird Bio Inc Récepteur d'antigène chimérique multivalent
CA3087331A1 (en) 2017-12-29 2019-07-04 City Of Hope Meditope-enabled t cells
WO2019134866A1 (en) 2018-01-03 2019-07-11 Molmed Spa Chimeric antigen receptors containing optimal spacer region
IL279063B2 (en) 2018-05-31 2026-05-01 Washington University St Louis Chimeric antigen receptor T cells for cancer treatment
EP3801301B1 (en) 2018-06-08 2026-01-28 Boston Scientific Scimed Inc. Occlusive device with actuatable fixation members
WO2019242632A1 (en) 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
WO2020001344A1 (en) 2018-06-29 2020-01-02 Beijing Biocytogen Co., Ltd ANTI-CD3e ANTIBODIES AND USES THEREOF
US12036242B2 (en) 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
KR20210074274A (ko) 2018-08-06 2021-06-21 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물
KR20210072797A (ko) 2018-10-05 2021-06-17 세인트 안나 킨더크렙스포르슝 키메라 항원 수용체(car) 그룹
JP2022512594A (ja) 2018-10-05 2022-02-07 ザンクト アンナ キンダークレプスフォルシュング キメラ抗原受容体(car)の群
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
CA3130489A1 (en) 2019-02-18 2020-08-27 Memorial Sloan-Kettering Cancer Center Combinations of multiple chimeric antigen receptors for immunotherapy
US20230348556A1 (en) 2019-02-21 2023-11-02 Arbele Limited Artificial immunosurveillance chimeric antigen receptor and cells expressing the same
AU2020232789B2 (en) 2019-03-06 2026-04-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3959307A4 (en) 2019-04-22 2023-08-23 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
EP3969482A1 (en) 2019-05-16 2022-03-23 University of Washington Lockr-mediated recruitment of car t cells
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN116987197A (zh) 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
EP3998286A4 (en) 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES
CN112390891B (zh) 2019-08-14 2022-06-03 苏州方德门达新药开发有限公司 嵌合抗原受体及其构建方法和应用
WO2021030586A1 (en) 2019-08-15 2021-02-18 City Of Hope Dual bispecific antibody compounds and uses thereof
US10697749B1 (en) 2019-10-04 2020-06-30 William L. Richey, Sr. Reed tube cane diameter measurement tool

Similar Documents

Publication Publication Date Title
Larson et al. Recent advances and discoveries in the mechanisms and functions of CAR T cells
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
HRP20230239T1 (hr) Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu
JP2023093469A (ja) 抗cd16a抗体のサイトカインとの組み合わせ
JP2022166297A (ja) 最適化された多機能性t細胞を含むキメラ受容体t細胞を使用する治療
US12448426B2 (en) Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
AU2025279705A1 (en) Combination therapy using a chimeric antigen receptor
JP2023071724A (ja) Cmvエピトープ
US20230312671A1 (en) Grp78 targeted adoptive cell therapy
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
Etxeberria et al. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
KR20210144740A (ko) T 세포 수용체 및 이의 사용 방법
JP2024016200A (ja) キメラ抗原受容体療法のt細胞の増殖動態及びその使用
JP2022524994A (ja) T細胞受容体及びその使用方法
JP2022523554A (ja) T細胞受容体及びその使用方法
KR20210149048A (ko) T 세포 수용체 및 이의 사용 방법
JP2023538012A (ja) 免疫細胞機能の改善
JP2025128204A (ja) 免疫細胞機能の改善
KR20210144739A (ko) T 세포 수용체 및 이의 사용 방법
WO2024083226A1 (zh) 抗体融合蛋白及其制备和应用
TW202300643A (zh) 用於增強幹細胞樣記憶t細胞工程改造之材料及方法
WO2023006975A2 (en) Chimeric proteins and methods of immunotherapy
TW202309269A (zh) 重組抗原呈現細胞
JP2020535832A (ja) マウス定常領域を伴うtcrを発現する細胞を選択的に増幅するための方法
JP2026031931A (ja) 標的化epha3及びその使用